Citations

Showing 10 of 108104 citations.

Integration of Pulmonary Mechanics in a Personalized Approach to Mechanical Ventilation
Cortes-Puentes, Gustavo A. , Holets, Steven R, Oeckler, Richard A.

Mayo Clinic

Respiratory Care | August 30, 2018 | Volume: 63 | Issue: 9 | Pages: 1194-1196

10.4187/respcare.06526 | PMID 30166416 Get It

P2925Outcomes of direct current cardioversion in adults with cardiac amyloidosis
El‐Am, Edward , Grogan, Martha , Ammash, Naser M., Melduni, Rowlens M. , Hodge, David O. , Lin, Grace , Dispenzieri, Angela , White, Richard D. , Noseworthy, Peter A. , Pislaru, Sorin V. , Nkomo, Vuyisile T.

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy565.p2925 Get It

Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
Benton, Christopher B. , Chien, Kelly S. , Tefferi, Ayalew , Rodríguez, José A. , Kwari, Monica, Pierce, Sherry , Hornbaker, Marisa, Santos, Margarida A. , Siguero, Mariano, Zblewski, Darci, Al‐Kali, Aref , Kantarjian, Hagop M. , Pardanani, Animesh , Garcia‐Manero, Guillermo , Rodriguez, Jose, Ravandi, Farhad , Daver, Naval , Jabbour, Elias , Jain, Nitin , Alvarado, Yesid , Maiti, Abhishek , Aitken, Marisa J.L. , Martinez, Sara, Hogan, William J. , Kantarjian, Hagop

Mayo Clinic

Hematological Oncology | August 30, 2018 | Volume: 37 | Issue: 1 | Pages: 96-102

10.1002/hon.2557 | PMID 30153704 Get It

AbstractTrabectedin is an FDA‐approved DNA minor groove binder that has activity against translocation‐associated sarcomas. Lurbinectedin is a next‐generation minor groove binder with preclinical activity against myeloid leukemia cells. A dose‐finding phase 1 clinical trial was performed in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with further assessment of safety and tolerability. Forty‐two patients with relapsed/refractory AML/MDS received lurbinectedin administered as a 1‐hour intravenous infusion in a 3 + 3 study design. Two dosing schedules were used: 3.5, 5, 7, or 6 mg on days 1 and 8 or 2, 3, 1, or 1.5 mg for 3 consecutive days on days 1 to 3. Three patients experienced dose‐limiting toxicities of rhabdomyolysis (grade 4), hyperbilirubinemia (grade 3), and oral herpes (grade 3) with the day 1 and 8 schedule. Otherwise, adverse events mainly consisted of gastrointestinal manifestations (n = 11), febrile neutropenia/infections (n = 4), pulmonary toxicity (n = 2), and renal failure (n = 2). The most common laboratory abnormalities observed were an increase in creatinine (93%) and anemia, neutropenia, and thrombocytopenia (100%). Overall, 33 of 42 patients (79%) had reduction in blasts in peripheral blood or bone marrow. One patient achieved a partial response and 2 patients a morphologic leukemia‐free state. Most (n = 30, 71%) were discontinued due to progressive disease. Early deaths occurred from disease‐related causes that were not attributable to lurbinectedin. Four patients with a chromosome 11q21‐23 abnormality had significantly greater bone marrow blast reduction than those without such abnormality, with decrease of 31 ± 14% (n = 4) vs 8 ± 8% (n = 16), respectively (P = .04). Overall, lurbinectedin was safe and tolerated using the schedules and dose levels tested. While no sustained remissions were observed, single‐agent lurbinectedin was transiently leukemia suppressive for some patients.
A Validated Score Predicts Acute Kidney Injury and Survival in Patients With Alcoholic Hepatitis
Ravi, Sujan, Cruz‐Lemini, M. , Altamirano, José , Simonetto, Douglas A. , Maiwall, Rakhi , Axley, Page , Richardson, Taylor, Desai, Vivek, Cabezas, Joaquín , Vargas, Vı́ctor , Kamath, Patrick S. , Shah, Vijay H. , Bataller, Ramón , Bataller, Ramon A , Simonetto, Douglas A , Vargas, Victor , Richardson, Taylor, Sarin, Shiv Kumar , Singal, Ashwani K. , Cabezas, Joaquín

Mayo Clinic

Liver Transplantation | August 30, 2018 | Volume: 24 | Issue: 12 | Pages: 1655-1664

10.1002/lt.25328 | PMID 30153377 Get It

Abstract Identifying patients at high risk for acute kidney injury (AKI) during hospitalization among patients admitted with severe alcoholic hepatitis (AH) is an unmet clinical need. We performed a multicentric prospective cohort study using data from 4 different cohorts on well‐characterized patients hospitalized with severe AH. Data collected on 773 AH patients from 4 cohorts across the globe were randomly split into test (n = 390) and validation (n = 383) cohorts. We found that 32% of the patients developed inpatient AKI in the test cohort. Approximately 60% of patients met criteria for systemic inflammatory response syndrome (SIRS) at admission. Hepatic encephalopathy, SIRS, and Model for End‐Stage Liver Disease score at admission predicted inpatient AKI with odds ratios of 3.86, 2.24, and 1.14, respectively. The AKI risk score developed using these predictors stratified risk of inpatient AKI to low (score <3), moderate (3‐4), and high (>4). These findings were replicated in the validation cohort. In the whole study cohort, patients with AKI had a lower 90‐day survival (53% versus 77%; P < 0.001). Those with AKI risk score of >4 had significantly lower 90‐day survival as compared with those with risk scores between 3 and 4 and <3 (47% versus 68% versus 88%; P < 0.001). In conclusion, AKI occurs frequently in AH patients and negatively impacts short‐term mortality. The AKI risk score is useful in identifying patients at high risk for inpatient AKI and may be useful for developing new therapeutic strategies to prevent AKI in patients with AH.
Symptoms of Autonomic Dysfunction Among Those With Persistent Posttraumatic Headache Attributed to Mild Traumatic Brain Injury: A Comparison to Migraine and Healthy Controls
Howard, Levi, Dumkrieger, Gina , Ross, Katherine , Berisha, Visar , Schwedt, Todd J. , Dumkrieger, Gina , Chong, Catherine D. , Berisha, Visar

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 30, 2018 | Volume: 58 | Issue: 9 | Pages: 1397-1407

10.1111/head.13396 | PMID 30156267 Get It

Background Most persistent posttraumatic headaches (PPTH) have a phenotype that meets diagnostic criteria for migraine or probable migraine. Although symptoms of autonomic dysfunction have been well described among those with migraine, the presence and relative severity of such symptoms among those with PPTH have yet to be reported. Objective The objective of this study was to assess and compare symptoms of autonomic dysfunction among those with PPTH attributed to mild traumatic brain injury (mTBI) vs migraine vs healthy controls using Composite Autonomic Symptom Score 31 (COMPASS‐31) questionnaire scores. Methods Individuals with PPTH (n = 56) (87.5% of whom had a migraine/probable migraine phenotype), migraine (n = 30), and healthy controls (n = 36) were prospectively assessed in this cross‐sectional cohort study using the COMPASS‐31 questionnaire. Total COMPASS‐31 scores and individual domain scores (bladder, gastrointestinal, orthostatic intolerance, pupillomotor, secretomotor, vasomotor) were compared between subject groups. Results COMPASS‐31 mean total weighted score was 37.22 ± 15.44 in the PPTH group, 27.15 ± 14.37 in the migraine group, and 11.67 ± 8.98 for healthy controls. COMPASS‐31 mean weighted total scores were significantly higher in those with PPTH vs migraine ( P = .014), for PPTH vs healthy controls ( P = .001), and for migraine vs healthy controls ( P = .001). Those with PPTH had numerically higher scores for all COMPASS‐31 domains compared to those with migraine, and the domain scores were significantly higher for orthostatic intolerance (PPTH = 4.80 ± 2.47 vs migraine = 3.33 ± 2.31, P = .027) and bladder (PPTH = 1.14 ± 1.45 vs migraine = 0.47 ± 0.73, P = .020). Among individuals with PPTH, post hoc correlations indicated a positive association between number of total lifetime TBIs with total weighted COMPASS‐31 scores (rho = 0.32, P = .020), between years lived with headache and vasomotor domain subscores (rho = 0.27; P = .044), and between headache frequency with vasomotor domain subscores (rho = 0.27; P = .041). Conclusions Symptoms of autonomic dysfunction were greatest among those with PPTH compared to migraine and healthy controls. Among individuals with PPTH, number of lifetime TBIs was associated with greater symptoms of autonomic dysfunction, while greater headache burden was associated with higher vasomotor domain autonomic dysfunction subscores, potentially indicating that PPTH patients with higher disease burden have an increased risk for having autonomic dysfunction. Symptoms of autonomic dysfunction should be ascertained during the clinical management of patients with PPTH and might be a characteristic that helps differentiate PPTH from migraine.
P2923Sudden cardiac death, heart failure and arrhythmias due to acute zika myocarditis
Carta, K Gonzalez, Mujica, I J Mendoza, Britto, Ivan J Mendoza, Morr, Igor, Meza, Yolimar, Finizola, Vicente, Terzic, Carmen M., Allison, Thomas, Martínez, N., Marques, Juan, Mujica, Ivan J Mendoza, Martinez, N

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy565.p2923 Get It

4934Circulating molecular forms of ANP and BNP in human acute decompensated Heart Failure: evidence for a relative ANP deficiency state
Reginauld, Shawn, Cannone, Valentina , Heublein, Denise M., Sangaralingham, Jeson, Burnett, J. C., Iyer, Seethalakshmi , Scott, Christopher G.

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy566.4934 Get It

Substance use disorders and their effect on the psychiatric and justice systems
Schmidt, Kristen A. , Lamoureux, Ian C., Schak, Kathryn M. , Lachner, Christian , Burton, Mary Caroline, Rummans, Teresa A. , Larrabee, Beth R.

Mayo Clinic

The American Journal on Addictions | August 30, 2018 | Volume: 27 | Issue: 7 | Pages: 574-577

10.1111/ajad.12789 | PMID 30152572 Get It

Background and ObjectivesA high proportion of persons in institutionalized settings such as the criminal justice system and psychiatric hospitals have substance use disorders (SUDs). We explored the association between substance use, demographics, and criminal justice involvement in a population of patients placed on involuntary 72‐h holds in a psychiatric facility.MethodsWe retrospectively identified patients aged 18 through 57 years who had been placed on 72‐h holds during an acute psychiatric hospitalization during a 1‐year period. Data were analyzed with standard descriptive statistics, and data collection was reviewed by 2 randomly assigned psychiatrists.ResultsWe identified 336 patients placed on 72‐h holds during an acute psychiatric stay. Of these, more than two‐thirds (68.5%; n = 230) had an SUD. Compared with patients not using substances, those with SUDs were significantly more likely to be younger (p = .003), male (p = .005), and unmarried (p < .001) and to have criminal justice involvement before (p < .001) and after hospitalization (p < .001). The rate of unemployment was similarly high in both users (67.4%) and nonusers (69.2%).Discussion and ConclusionsMost patients on involuntary psychiatric holds have comorbid SUDs. These patients are more likely to have interacted with the criminal justice system and less likely to have social support in the form of marriage. Unemployment was common among all patients.Scientific SignificanceWhen SUDs are not treated by the criminal justice or mental health system, rehospitalization and criminal recidivism may result. (Am J Addict 2018;27:574–577)
P242Cardiovascular vigor derived from exercise capacity and heart rate recovery is a strong predictor of long-term survival in older adults
Sydó, Tibor, Murphy, J G, Allison, Thomas G. , Sydó, Nóra , Merkely, Béla , López-Jiménez, Francisco

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy564.p242 Get It

P3664Left ventricular post-infarct remodelling: temporal patterns and left ventricular functional evolution
Bijl, Pieter van der , Abou, Rachid , Goedemans, Laurien, Holmes, David R. , Gersh, Bernard J. , Marsan, Nina Ajmone , Delgado, Victoria , Bax, Jeroen J.

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy563.p3664 Get It